Heart rate after cardiac transplantation - Lessons from the tortoise and the shrew

Transplantation

Volumn 95, Issue 2, 2013, Pages 259-265

  Critchley, William R ^a,b   Yonan, Nizar ^b   Shaw, Steven M ^b,c   Fildes, James E ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac transplantation; Endothelial stress.; Graft rejection; Tachycardia

Indexed keywords

ADENOSINE TRIPHOSPHATE; CATECHOLAMINE; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ARTERIAL STIFFNESS; BIOACCUMULATION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CYTOKINE RESPONSE; DISEASE EXACERBATION; ENERGY TRANSFER; EVOLUTIONARY ADAPTATION; EXERCISE; HEART ATRIUM FIBRILLATION; HEART DENERVATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE VARIABILITY; HEART TRANSPLANTATION; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; METABOLIC RATE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SINUS TACHYCARDIA;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ENERGY METABOLISM; GRAFT REJECTION; GRAFT SURVIVAL; HEART RATE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL CONTRACTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; SHREWS; TACHYCARDIA; TURTLES; VASCULAR STIFFNESS;

EID: 84872973924     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826bc42a     Document Type: Review

References (63)

1. Doesch AO, Celik S, Ehlermann P, et al. Heart rate reduction after heart transplantation with beta-blocker versus the selective if channel antagonist ivabradine. Transplantation 2007; 84: 988.
2. Doesch AO, Ammon K, Konstandin M, et al. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 2009; 88: 835.
3. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951.
4. Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987; 113: 1489.
5. Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association detection project in industry. Am J Epidemiol 1999; 149: 853.
6. Dobson GP. On being the right size: heart design, mitochondrial efficiency and lifespan potential. Clin Exp Pharmacol Physiol 2003; 30: 590.
7. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211.
8. Yamamoto E, Lai ZF, Yamashita T, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006; 24: 2057.
9. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 1999; 274: 6272.
10. Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161.
11. Tang D, Kang R, Livesey KM, et al. High mobility group box 1 (hmgb1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011; 15: 2185.
12. Yu Y, Liu M, Zhang L, et al. Heat shock transcription factor 1 inhibits h(2)o (2)-induced cardiomyocyte death through suppression of highmobility group box 1. Mol Cell Biochem 2012; 364: 263.
13. Critchley WR, Fildes JE. Graft rejectionVendogenous or allogeneic? Immunology 2012; 136 123.
14. Fan J, Frey RS, Malik AB. Tlr4 signaling induces tlr2 expression in endothelial cells via neutrophil nadph oxidase. J Clin Invest 2003; 112: 1234.
15. Prange HD, Jackson DC. Ventilation, gas exchange and metabolic scaling of a sea turtle. Respir Physiol 1976; 27: 369.
16. Hertz MI, Aurora P, Benden C, et al. Scientific registry of the international society for heart and lung transplantation: introduction to the 2011 annual reports. J Heart Lung Transplant 2011; 30: 1071.
17. Dang EV, Barbi J, Yang HY, et al. Control of t(h)17/t(reg) balance by hypoxia-inducible factor 1. Cell 146: 772.
18. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of cd4 th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133.
19. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30: 1104.
20. Jurgens KD, Fons R, Peters T, et al. Heart and respiratory rates and their significance for convective oxygen transport rates in the smallest mammal, the Etruscan shrew Suncus etruscus. J Exp Biol 1996; 199: 2579.
21. Fu YC, Chi CS, Yin SC, et al. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc Res 2004; 62: 558.
22. Torres KC, Antonelli LR, Souza AL, et al. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 2005; 166: 144.
23. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202.
24. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S.
25. Burstein B, Comtois P, Michael G, et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009; 105: 1213.
26. Wang JM, Huang YJ, Wang Y, et al. Increased circulating cd31+/cd42- microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens 2007; 20: 957.
27. Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29: 1277.
28. Arimura K, Egashira K, Nakamura R, et al. Increased inactivation of nitric oxide is involved in coronary endothelial dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2001; 280: H68.
29. Khan UA, Williams SG, Fildes JE, et al. The pathophysiology of chronic graft failure in the cardiac transplant patient. Am J Transplant 2009; 9: 2211.
30. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185.
31. Oestreicher EM, Martinez-Vasquez D, Stone JR, et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin ii/ng-nitro-l-arginine methyl ester-induced myocardial injury. Circulation 2003; 108: 2517.
32. Richter M, Skupin M, Grabs R, et al. New approach in the therapy of chronic rejection? Ace- and at1-blocker reduce the development of chronic rejection after cardiac transplantation in a rat model. J Heart Lung Transplant 2000; 19: 1047.
33. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809.
34. Hayashi H, Kobara M, Abe M, et al. Aldosterone nongenomically produces nadph oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 2008; 31: 363.
35. Yang CW, Ahn HJ, Kim WY, et al. Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporinetreated rat kidney. Kidney Int 2001; 60: 847.
36. Denzel MS, Scimia MC, Zumstein PM, et al. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010; 120: 4342.
37. Tsang JY, Li D, Ho D, et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol 2111; 11: 604.
38. Ishihara T, Haraguchi G, Konishi M, et al. Effect of adiponectin on cardiac allograft vasculopathy. Circ J 2011; 75: 2005.
39. Beatty AL, Zhang MH, Ku IA, et al. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the heart and soul study. Atherosclerosis 2012; 220: 587.
40. Yin WH, Chen YH, Wei J, et al. Associations between endothelin-1 and adiponectin in chronic heart failure. Cardiology 2011; 118: 207.
41. Dupuis J, Moe GW, Cernacek P. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovasc Res 1998; 39: 609.
42. Yang LL, Gros R, Kabir MG, et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 2004; 109: 255.
43. Coulombe M, Battistini B, Stankova J, et al. Endothelins regulate mediator production of rat tissue-cultured mucosal mast cells. Upregulation of th1 and inhibition of th2 cytokines. J Leukoc Biol 2002; 71: 829.
44. Graff GR, Gozal D. Cardiorespiratory responses to interleukin-1beta in adult rats: role of nitric oxide, eicosanoids and glucocorticoids. Arch Physiol Biochem 1999; 107: 97.
45. Ock S, Ahn J, Lee SH, et al. Receptor activator of nuclear factorkappab ligand (rankl) is a novel inducer of myocardial inflammation. Cardiovasc Res. 2012; 94: 105.
46. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein hmgb1 by necrotic cells triggers inflammation. Nature 2002; 418: 191.
47. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279.
48. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated highmobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571.
49. Duan L, Wang CY, Chen J, et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing il-6-dependent th17 alloreactive response. Lab Invest 2011; 91: 43.
50. Zhang P, Cox CJ, Alvarez KM, et al. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol 2009; 183: 27.
51. Nakamura R, Egashira K, Machida Y, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 2002; 106: 362.
52. Vande Kappelle RP, Gambetta K, Deal BJ, et al. Late sinus and atrial tachycardia after pediatric heart transplantation might predict poor outcome. Pediatr Cardiol 2010; 31: 643.
53. Park JK, Hsu DT, Hordof AJ, et al. Arrhythmias in pediatric heart transplant recipients: prevalence and association with death, coronary artery disease, and rejection. J Heart Lung Transplant 1993; 12: 956.
54. Anand RG, Reddy MT, Yau CL, et al. Usefulness of heart rate as an independent predictor for survival after heart transplantation. Am J Cardiol 2009; 103: 1290.
55. Scott CD, McComb JM, Dark JH. Heart rate and late mortality in cardiac transplant recipients. Eur Heart J 1993; 14: 530.
56. Schwaiblmair M, von Scheidt W, Uberfuhr P, et al. Functional significance of cardiac reinnervation in heart transplant recipients. J Heart Lung Transplant 1999; 18: 838.
57. Vanderlaan RD, Conway J, Manlhiot C, et al. Enhanced exercise performance and survival associated with evidence of autonomic reinnervation in pediatric heart transplant recipients. Am J Transplant 2012; 12: 2157.
58. Jones DG, Mortsell DH, Rajaruthnam D, et al. Permanent pacemaker implantation early and late after heart transplantation: clinical indication, risk factors and prognostic implications. J Heart Lung Transplant 2011; 30: 1257.
59. Cantillon DJ, Gorodeski EZ, Caccamo M, et al. Long-term outcomes and clinical predictors for pacing after cardiac transplantation. J Heart Lung Transplant 2009; 28: 791.
60. Cantillon DJ, Tarakji KG, Hu T, et al. Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of the unos/optn cardiac transplant database. Heart Rhythm 2010; 7: 1567.
61. Strobel JS, Epstein AE, Bourge RC, et al. Nonpharmacologic validation of the intrinsic heart rate in cardiac transplant recipients. J Interv Card Electrophysiol 1999; 3: 15.
62. Dasari TW, Pavlovic-Surjancev B, Patel N, et al. Incidence, risk factors, and clinical outcomes of atrial fibrillation and atrial flutter after heart transplantation. Am J Cardiol 2010; 106: 737.
63. Izrailtyan I, Kresh JY, Morris RJ, et al. Early detection of acute allograft rejection by linear and nonlinear analysis of heart rate variability. J Thorac Cardiovasc Surg 2000; 120: 737.